About virusinacti veted fresh
Pathogen-reduced human plasma
Used for
- Replaces multiple clotting factors during major bleeding or complex surgery.
- Treats clotting-factor deficiencies when specific factor concentrates are unavailable or unsuitable.
- Supports plasma exchange in thrombotic thrombocytopenic purpura.
Usual adult dose
Dose is guided by bleeding, clotting tests, and body weight; commonly 10–15 mL/kg initially.
Usual dose in children
Dose is guided by bleeding and clotting tests; commonly 10–15 mL/kg initially.
Common side effects
- Allergic reactions, including severe anaphylaxis
- Fever, chills, nausea, or rash
- Fluid overload and breathing difficulty
- Rare blood clots or transfusion-related lung injury
Important warnings
- Given by intravenous infusion under medical supervision.
- May cause serious allergic reactions or transfusion-related complications.
- Use cautiously in heart failure or risk of fluid overload.
- Not suitable for patients with severe immunoglobulin A deficiency and anti-IgA antibodies.
Pregnancy
May be used when clinically necessary; evidence in pregnancy is limited.
Breastfeeding
No specific harm is expected, but data are limited.
Interactions
- No specific medicine interactions are established; monitor alongside other blood products and treatments.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.